HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway

HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway

Background Lung adenocarcinoma is one of the most common tumors, and cisplatin is frequently used in treating lung adenocarcinoma patients. This study aimed to look into the roles and mechanisms of HNF4G in cisplatin resistance of lung adenocarcinoma. Materials & Methods Cisplatin resistance and...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Jiaqi Liang, Guangyin Zhao, Yunyi Bian, Guoshu Bi, Qihai Sui, Huan Zhang, Haochun Shi, Guangyao Shan, Yiwei Huang, Zhencong Chen, Lin Wang, Cheng Zhan
Materialtyp: Artikel
Språk:English
Publicerad: PeerJ Inc. 2023-03-01
Serie:PeerJ
Ämnen:
Lung adenocarcinoma
Cisplatin
HNF4G
MAPK6
Transcription factor
Länkar:https://peerj.com/articles/14996.pdf

Internet

https://peerj.com/articles/14996.pdf

Liknande verk